MX2023000801A - Compuestos lipidicos que comprenden al menos un radical terminal de formula -nh-cx-a o -nh-cx-nh-a, composiciones que los contienen y usos de los mismos. - Google Patents

Compuestos lipidicos que comprenden al menos un radical terminal de formula -nh-cx-a o -nh-cx-nh-a, composiciones que los contienen y usos de los mismos.

Info

Publication number
MX2023000801A
MX2023000801A MX2023000801A MX2023000801A MX2023000801A MX 2023000801 A MX2023000801 A MX 2023000801A MX 2023000801 A MX2023000801 A MX 2023000801A MX 2023000801 A MX2023000801 A MX 2023000801A MX 2023000801 A MX2023000801 A MX 2023000801A
Authority
MX
Mexico
Prior art keywords
radical
formula
sub
lipidic compounds
lnps
Prior art date
Application number
MX2023000801A
Other languages
English (en)
Inventor
Jean Haensler
Luc Even
Benoît Frisch
Manon Ripoll
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of MX2023000801A publication Critical patent/MX2023000801A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Pyridine Compounds (AREA)

Abstract

La divulgación se refiere a nuevos compuestos lipídicos, nanopartículas lipídicas (LNP) que contienen los mismos, y al uso de los compuestos lipídicos o las LNP para la administración de ácido nucleico. Los compuestos lipídicos como se divulga en la presente memoria comprenden al menos un radical terminal de fórmula (I): *-NH-CX-(NH)n-A (I) en donde: - *- representa un enlace sencillo que une dicho radical de fórmula (I), directamente o no, a un grupo de cola lipófilo o hidrófobo C10 a C55; - n es 0 o 1; - X es un átomo de oxígeno o de azufre, y - A representa un radical heterocíclico insaturado de 5 o 6 miembros opcionalmente sustituido o un radical de anillo heteroaromático de 5 o 6 miembros, conteniendo ambos al menos un átomo de nitrógeno; o una de las sales farmacéuticamente aceptables de dicho radical de fórmula (I); y con dicho compuesto que está en todas las formas isoméricas posibles racémicas, enantioméricas y diastereoisoméricas.
MX2023000801A 2020-07-17 2021-07-16 Compuestos lipidicos que comprenden al menos un radical terminal de formula -nh-cx-a o -nh-cx-nh-a, composiciones que los contienen y usos de los mismos. MX2023000801A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20305825 2020-07-17
PCT/EP2021/070026 WO2022013443A1 (en) 2020-07-17 2021-07-16 Lipidic compounds comprising at least one terminal radical of formula -nh-cx-a or -nh-cx-nh-a, compositions containing them and uses thereof

Publications (1)

Publication Number Publication Date
MX2023000801A true MX2023000801A (es) 2023-02-27

Family

ID=72292468

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000801A MX2023000801A (es) 2020-07-17 2021-07-16 Compuestos lipidicos que comprenden al menos un radical terminal de formula -nh-cx-a o -nh-cx-nh-a, composiciones que los contienen y usos de los mismos.

Country Status (11)

Country Link
US (1) US20230295097A1 (es)
EP (1) EP4182302A1 (es)
JP (1) JP2023533864A (es)
KR (1) KR20230041744A (es)
CN (1) CN116134020A (es)
AU (1) AU2021308443A1 (es)
BR (1) BR112023000855A2 (es)
CA (1) CA3189385A1 (es)
IL (1) IL299791A (es)
MX (1) MX2023000801A (es)
WO (1) WO2022013443A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117243922A (zh) * 2022-04-29 2023-12-19 北京剂泰医药科技有限公司 脂质纳米颗粒
CN117491546A (zh) * 2023-06-30 2024-02-02 厦门赛诺邦格生物科技股份有限公司 一种聚乙二醇化脂质含量的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3681379A (en) * 1969-04-26 1972-08-01 Basf Ag 2-carbamyl-2-imidazolines and method for their production
US4179277A (en) * 1976-03-12 1979-12-18 Bayer Aktiengesellschaft 4,5-Dichloroimidazole-2-carboxylic acid derivatives
FR2729947A1 (fr) * 1995-01-31 1996-08-02 Oreal Nouveaux derives de lysine, procede de preparation, utilisations et compositions les comprenant
ES2702466T3 (es) 2013-08-21 2019-03-01 Curevac Ag Procedimiento para aumentar la expresión de proteínas codificadas por ARN
WO2018187590A1 (en) * 2017-04-05 2018-10-11 Modernatx, Inc. Reduction or elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
US20190314291A1 (en) * 2018-01-30 2019-10-17 Modernatx, Inc. Compositions and methods for delivery of agents to immune cells

Also Published As

Publication number Publication date
BR112023000855A2 (pt) 2023-03-07
CN116134020A (zh) 2023-05-16
AU2021308443A1 (en) 2023-03-16
EP4182302A1 (en) 2023-05-24
WO2022013443A1 (en) 2022-01-20
CA3189385A1 (en) 2022-01-20
IL299791A (en) 2023-03-01
KR20230041744A (ko) 2023-03-24
JP2023533864A (ja) 2023-08-04
US20230295097A1 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
MX2023000801A (es) Compuestos lipidicos que comprenden al menos un radical terminal de formula -nh-cx-a o -nh-cx-nh-a, composiciones que los contienen y usos de los mismos.
PE20210655A1 (es) Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa
TW200512184A (en) 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
TW200621156A (en) Fungicidal composition containing acid amide derivative
RU2008123839A (ru) Соединение оксазола и фармацевтическая композиция
ES8404330A1 (es) Un metodo para la produccion de derivados de esteres de acidos 1,4-dihidropiridin-3,5-dicarboxilicos.
CA2394086A1 (fr) Derives de 4-aminopiperidine et leur utilisation en tant que medicament
JP2008509166A5 (es)
PE20050480A1 (es) Acido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0] non-1(7)-en-2-il)alquil]fosfonico y derivados
EP0092391A3 (en) Novel piperidine derivatives and pharmaceutical compositions containing same
KR910014123A (ko) 여기 아미노산 신경전달체의 길항 물질로서 유용한 폴리아민
NO20053715L (no) 10,10-dialkylprostanoinsyrederivater som midler for a senke intraokulaert trykk
EP0309422A3 (en) New amidino tricycle derivatives
RU2007132179A (ru) Ингибирующие вич производные 2-(4-цианофениламино)пиримидина
MY135191A (en) Imidazopyridine derivatives, preparation method and pharmaceutical compositions containing same
JPS57145850A (en) Novel carboxylic acid amide and medicine
KR960031422A (ko) 신규한 레티노이드
MX2023010937A (es) Derivados de morfolinas sustituidas y usos de estos.
PE20060696A1 (es) Inhibidores de la adenilato ciclasa soluble
EP0309424A3 (en) New amidino derivatives
EP0656355A4 (en) BIPHENYLMETHANE DERIVATIVE AND MEDICINE CONTAINING THE SAME.
LV5768A4 (lv) ÚÚÚ(3-Piridinil)metilen¾amino¾oksi¾alkanskabes un esteri
EA200500716A1 (ru) Новые соединения 2,3-дигидро-4-(1h)-пиридона, способ их получения и фармацевтические композиции, которые их содержат
GB1347930A (en) Imidazolines and a proces for the preparation thereof
MX2023000802A (es) Compuestos lipidicos escindibles, composiciones que los contienen y usos de los mismos.